| The development of anticancer ruthenium (II) complexes: from single molecule compounds to nanomaterials L Zeng, P Gupta, Y Chen, E Wang, L Ji, H Chao, ZS Chen Chemical Society Reviews 46 (19), 5771-5804, 2017 | 880 | 2017 |
| The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade RJ Kathawala, P Gupta, CR Ashby Jr, ZS Chen Drug resistance updates 18, 1-17, 2015 | 756 | 2015 |
| Modulating ROS to overcome multidrug resistance in cancer Q Cui, JQ Wang, YG Assaraf, L Ren, P Gupta, L Wei, CR Ashby Jr, ... Drug Resistance Updates 41, 1-25, 2018 | 473 | 2018 |
| Multidrug resistance proteins (MRPs) and cancer therapy YK Zhang, YJ Wang, P Gupta, ZS Chen The AAPS journal 17, 802-812, 2015 | 204 | 2015 |
| Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance N Anreddy, P Gupta, RJ Kathawala, A Patel, JND Wurpel, ZS Chen Molecules 19 (9), 13848-13877, 2014 | 116 | 2014 |
| Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters YF Fan, W Zhang, L Zeng, ZN Lei, CY Cai, P Gupta, DH Yang, Q Cui, ... Cancer letters 421, 186-198, 2018 | 108 | 2018 |
| Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1-and ABCG2-overexpressing cancer cells N Ji, Y Yang, CY Cai, ZN Lei, JQ Wang, P Gupta, S Shukla, SV Ambudkar, ... Cancer letters 440, 82-93, 2019 | 99 | 2019 |
| Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: in vitro and in vivo study YJ Wang, YK Zhang, GN Zhang, SB Al Rihani, MN Wei, P Gupta, ... Cancer letters 396, 145-154, 2017 | 66 | 2017 |
| Discovery of 5-cyano-6-phenylpyrimidin derivatives containing an acylurea moiety as orally bioavailable reversal agents against P-glycoprotein-mediated mutidrug resistance B Wang, LY Ma, JQ Wang, ZN Lei, P Gupta, YD Zhao, ZH Li, Y Liu, ... Journal of medicinal chemistry 61 (14), 5988-6001, 2018 | 63 | 2018 |
| Voruciclib, a potent CDK4/6 inhibitor, antagonizes ABCB1 and ABCG2-mediated multi-drug resistance in cancer cells P Gupta, YK Zhang, XY Zhang, YJ Wang, KW Lu, T Hall, R Peng, ... Cellular Physiology and Biochemistry 45 (4), 1515-1528, 2018 | 58 | 2018 |
| Olmutinib (BI1482694/HM61713), a novel epidermal growth factor receptor tyrosine kinase inhibitor, reverses ABCG2-mediated multidrug resistance in cancer cells W Zhang, YF Fan, CY Cai, JQ Wang, QX Teng, ZN Lei, L Zeng, P Gupta, ... Frontiers in pharmacology 9, 1097, 2018 | 56 | 2018 |
| Tetrandrine interaction with ABCB1 reverses multidrug resistance in cancer cells through competition with anti-cancer drugs followed by downregulation of ABCB1 expression D Liao, W Zhang, P Gupta, ZN Lei, JQ Wang, CY Cai, AAD Vera, L Zhang, ... Molecules 24 (23), 4383, 2019 | 54 | 2019 |
| Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: in vitro and in vivo GN Zhang, YK Zhang, YJ Wang, P Gupta, CR Ashby Jr, S Alqahtani, ... Cancer letters 424, 19-29, 2018 | 54 | 2018 |
| Osimertinib (AZD9291), a mutant-selective EGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells XY Zhang, YK Zhang, YJ Wang, P Gupta, L Zeng, M Xu, XQ Wang, ... Molecules 21 (9), 1236, 2016 | 54 | 2016 |
| VS-4718 antagonizes multidrug resistance in ABCB1-and ABCG2-overexpressing cancer cells by inhibiting the efflux function of ABC transporters N Ji, Y Yang, CY Cai, ZN Lei, JQ Wang, P Gupta, QX Teng, ZS Chen, ... Frontiers in Pharmacology 9, 1236, 2018 | 52 | 2018 |
| Anti-cancer effect of Indanone-based thiazolyl hydrazone derivative on colon cancer cell lines S Narayanan, P Gupta, U Nazim, M Ali, N Karadkhelkar, M Ahmad, ... The International Journal of Biochemistry & Cell Biology 110, 21-28, 2019 | 50 | 2019 |
| Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo AA De Vera, P Gupta, Z Lei, D Liao, S Narayanan, Q Teng, SE Reznik, ... Cancer letters 442, 91-103, 2019 | 50 | 2019 |
| Ulixertinib (BVD-523) antagonizes ABCB1-and ABCG2-mediated chemotherapeutic drug resistance N Ji, Y Yang, ZN Lei, CY Cai, JQ Wang, P Gupta, X Xian, DH Yang, ... Biochemical Pharmacology 158, 274-285, 2018 | 49 | 2018 |
| Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition JJ Lin, A Langenbucher, P Gupta, S Yoda, IJ Fetter, M Rooney, A Do, ... NPJ precision oncology 4 (1), 21, 2020 | 44 | 2020 |
| Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance CY Cai, H Zhai, ZN Lei, CP Tan, BL Chen, ZY Du, JQ Wang, YK Zhang, ... European journal of medicinal chemistry 179, 849-862, 2019 | 32 | 2019 |
